Skip to Main Content

Preston C. Sprenkle, MD

Associate Professor of Urology; Division Chief, Division of Urology at VA Connecticut Healthcare System; Director, Urology Research Fellowship; Director, Urologic Oncology Clinical Fellowship Program



Dr. Preston C. Sprenkle specializes in the treatment of urologic cancers, including prostate cancer, kidney cancer, bladder cancer, testicular cancer and sarcoma – a rare kind of cancer that grows in cells that connect or support other parts of the body, like bone or muscle.

Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device. This machine, introduced in 2009, allows a surgeon to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors.

“Skilled and experienced radiologists are rare for this relatively new technique,” Dr. Sprenkle explains. “At Yale, we are fortunate to have some of the world leaders in prostate MRI.”

Dr. Sprenkle is also a pioneer in “focal therapy,” which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This avoids many of the side effects—such as erectile dysfunction and incontinence—that may follow the removal of the whole prostate.

“Exciting technological advances are revolutionizing urology. Prostate cancer is very common and current treatments can majorly impact a man's sexual and urinary function,” Dr. Sprenkle says. “Developing ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life is tremendously rewarding.”

Dr. Sprenkle believes in working with patients to come up with individualized treatment plans. “I want my patients to feel that I hear their concerns and treat them like a person. I am pleased at the end of a long consultation when they feel like they understand their disease and their options.”

Education & Training

  • Fellowship
    Memorial Sloan Kettering Cancer Center (2011)
  • Residency
    New York Presbyterian Hospital (2009)
  • Internship
    New York Presbyterian Hospital (2005)
  • MD
    Columbia University (2004)
  • BA
    Stanford University, Human Biology (1998)


  • Grand Round Presentation "Management of T1 Bladder Cancer"
    Brooklyn, United States 2011
  • Annual Meeting, Society of Urologic Oncology "B7x is a seum marker for prostate cancer."
    Bethseda, United States 2009
  • Annual Meeting, American Urological Association, "The bladder trigone is not a Wolffian duct remnant."
    San Francisco, United States 2006

Honors & Recognition

AwardAwarding OrganizationDate
Best Poster Podium PresentationYoung Urologic Oncologist dinner, Society Of Urologic Oncology Annual Meeting2009
Finalist - NY section AUA Valentine Essay ContestNY Academy of Medicine2009
Finalist - NY section AUA Valentine Essay ContestNY Academy of Medicine2007
First Prize - NY section AUA Valentine Essay ContestNY Academy of Medicine2006
Arnold P. Gold Humanism in Medicine Honors Society2004
Alpha Omega Alpha Medical School Honors Society2004
Outstanding Member of Stanford CommunityStanford University1998
Member, Board of DirectorsStanford University Alumni Association1997

Professional Service

NCCN Prostate Cancer Early Detection Panel2014
"Journal of Urology"Reviewer2009 - 2015
"Frontiers in Science"Reviewer2009 - 2015
"Urology"Reviewer2009 - 2015
Washington Heights free prostate cancer education and screening clinicParticipant2008

Departments & Organizations